MultiVir, a biotech developing gene therapies for cancer, withdrew its plans for an initial public offering on Wednesday.
The company had planned to raise $60 million but postponed its US IPO earlier this month.
The Houston, TX-based company was founded in 2009 and had planned to list on the NASDAQ under the symbol MVIR. RBC Capital Markets was set to be the sole bookrunner on the deal.
